CDKN2A and breast carcinoma: As previous studies reported, CDKN2A-mediated molecular subtypes identified drug sensitivity differences in afatinib, erlotinib, and lapatinib, and the higher expression of CDKN2A implied worse outcomes and molecular subtypes in breast cancer.